Decode Age: Leading in Longevity Science

Bengaluru-based longevity science startup Decode Age has successfully raised Rs 14.48 crore (approximately $1.7 million) in a pre-Series A funding round, with Krishna Prasad Chigurupati, chairman and managing director of Granules India, at the helm. Established in 2021, Decode Age operates at the crossroads of aging biology, biomarkers, and the science of gut microbiomes. The main aim of the company is to render aging-related biological signals measurable and applicable, employing testing, research, and precision-guided interventions.

Funding to Propel Research Efforts

The funds obtained will be allocated towards enhancing Decode Age’s biomarker discovery initiatives, bolstering its multi-omics and microbiome research pipeline, and refining its scientific and analytical facilities. The organization is also dedicated to developing research-supported supplements and longevity solutions associated with various aging pathways, including metabolism, inflammation, cellular energy, and cognitive health.

Innovative Platforms and Services

Decode Age has created an in-house platform that encompasses genome-scale gut microbiome analysis, metagenomics, and biomarker research. These advanced systems are tailored to aid clinicians, researchers, and individuals who are in search of data-driven insights into prolonged health and aging.

Expansion and Collaborations

As it aims to extend its longevity research beyond the borders of India, the startup is actively expanding its scientific and product teams. Moreover, it works in collaboration with academic institutions and global research initiatives, including partnerships linked to the Indian Institute of Science (IISc) and various international longevity programmes, to produce microbiome and aging data that aligns with worldwide research standards.